• Home
  •  / Baxter International

Baxter International

OverviewSuggest Edit

Baxter International develops, manufactures and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operates through three segments: BioScience, Medication Delivery, and Renal. It offers peritoneal dialysis and hemodialysis, renal replacement therapies and other organ support therapies, sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, drug reconstitution devices, and parenteral nutrition therapies.
TypePublic
Founded1931
HQDeerfield, USMap
Websitebaxter.com
Employee Ratings3.5More
Culture scoreDMore
View Jobs (953)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)50,000
Job Openings953
Revenue (FY, 2019)$11.4 B(+3%)
Share Price (May 2020)$86.9

Key People/Management at Baxter International

Jose Almeida

Jose Almeida

Chairman, President and Chief Executive Officer
E. Almeida

E. Almeida

​Chairman, President and Chief Executive Officer
Amy A. Wendell

Amy A. Wendell

Director
Giuseppe Accogli

Giuseppe Accogli

​Senior Vice President and President, Americas
Wil Boren

Wil Boren

President, Advanced Surgery
Scott Bohaboy

Scott Bohaboy

Senior Vice President, Treasurer and Head of Global Planning
Show more

Baxter International Office Locations

Baxter International has offices in Deerfield, Baltimore, Bedford, Bloomington and in 34 other locations
Deerfield, US (HQ)
1 Baxter Pkwy
Baltimore, US
Baltimore, MD, USA
Bedford, US
Bedford, TX, USA
Bloomington, US
Bloomington, IN, USA
Cambridge, US
Cambridge, MA, USA
Cleveland, US
Cleveland, OH, USA
Show all (38)

Baxter International Financials and Metrics

Baxter International Revenue

Embed Graph
View revenue for all periods
Baxter International's revenue was reported to be $11.36 b in FY, 2019
USD

Revenue (Q1, 2020)

2.8b

Gross profit (Q1, 2020)

1.2b

Gross profit margin (Q1, 2020), %

41.5%

Net income (Q1, 2020)

333.0m

EBIT (Q1, 2020)

409.0m

Market capitalization (22-May-2020)

44.2b

Closing stock price (22-May-2020)

86.9

Cash (31-Mar-2020)

4.1b

EV

41.1b
Baxter International's current market capitalization is $44.2 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.2b10.6b11.1b11.4b

Revenue growth, %

2%4%5%

Cost of goods sold

6.1b6.1b6.3b6.6b

Gross profit

4.1b4.5b4.8b4.8b
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

2.4b2.6b2.6b2.5b2.6b2.7b2.7b2.8b2.8b2.6b2.8b2.9b2.8b

Cost of goods sold

1.4b1.6b1.5b1.4b1.5b1.6b1.6b1.6b1.5b1.6b1.7b1.6b1.6b

Gross profit

965.0m972.0m1.1b1.0b1.1b1.1b1.1b1.2b1.2b1.1b1.2b1.2b1.2b

Gross profit Margin, %

41%38%42%42%43%42%42%44%45%41%41%43%42%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.7b2.9b3.3b2.7b2.9b2.2b2.8b3.4b1.8b3.3b

Accounts Receivable

2.3b2.4b2.4b1.8b1.8b1.9b

Prepaid Expenses

345.0m402.0m418.0m601.0m622.0m619.0m

Inventories

2.4b2.6b2.8b3.5b3.6b1.6b1.4b1.5b1.7b1.7b
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

2.7b2.3b2.8b2.2b2.0b2.3b2.3b2.4b3.2b2.7b6.0b2.4b2.0b1.9b2.1b2.5b6.7b2.0b2.2b2.6b2.6b2.9b3.8b3.5b2.9b2.9b2.9b1.9b2.9b3.0b4.1b

Accounts Receivable

2.3b2.1b2.2b2.4b2.5b2.3b2.3b2.2b2.3b2.3b2.3b2.8b2.7b2.9b2.8b2.6b2.9b1.8b1.8b1.8b1.7b1.6b1.7b1.7b1.8b1.8b1.8b1.8b1.9b1.8b1.9b

Prepaid Expenses

611.0m619.0m647.0m677.0m652.0m696.0m767.0m740.0m759.0m843.0m785.0m874.0m883.0m871.0m850.0m1.1b1.1b1.3b951.0m711.0m634.0m603.0m619.0m633.0m621.0m628.0m624.0m626.0m651.0m672.0m637.0m

Inventories

2.5b2.4b2.5b2.5b2.6b2.6b2.7b2.7b2.8b3.0b3.1b3.6b3.7b3.8b3.7b3.5b3.8b1.7b1.7b1.6b1.6b1.5b1.5b1.6b1.6b1.6b1.7b1.8b1.8b1.7b1.7b
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

1.4b2.2b2.3b2.0b2.5b968.0m5.0b717.0m1.6b1.0b

Depreciation and Amortization

685.0m670.0m712.0m761.0m785.0m789.0m

Inventories

20.0m(315.0m)(129.0m)(311.0m)(439.0m)1.6b80.0m76.0m(197.0m)4.0m

Accounts Payable

(5.0m)98.0m18.0m84.0m53.0m(212.0m)
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(60.0m)472.0m997.0m570.0m1.2b1.8b588.0m1.2b1.8b552.0m1.1b1.7b556.0m1.1b1.5b430.0m762.0m763.0m3.4b4.6b4.7b272.0m537.0m788.0m389.0m732.0m1.3b347.0m690.0m1.0b333.0m

Depreciation and Amortization

166.0m335.0m506.0m158.0m327.0m503.0m175.0m355.0m534.0m183.0m366.0m573.0m236.0m489.0m747.0m295.0m497.0m593.0m189.0m395.0m599.0m194.0m378.0m562.0m192.0m387.0m594.0m195.0m393.0m580.0m199.0m

Inventories

94.0m(119.0m)(94.0m)(61.0m)(214.0m)(272.0m)(72.0m)(100.0m)(136.0m)(181.0m)(306.0m)(412.0m)(233.0m)(360.0m)(468.0m)(207.0m)(439.0m)(205.0m)(26.0m)(25.0m)(11.0m)(29.0m)(38.0m)(56.0m)(134.0m)(236.0m)(82.0m)(91.0m)(88.0m)(83.0m)

Accounts Payable

(107.0m)(162.0m)(57.0m)(135.0m)(124.0m)(90.0m)(288.0m)(224.0m)(282.0m)(299.0m)(171.0m)(56.0m)(236.0m)(222.0m)(154.0m)(383.0m)(34.0m)14.0m(438.0m)(343.0m)(326.0m)(262.0m)(112.0m)(36.0m)(103.0m)(109.0m)(51.0m)(310.0m)(308.0m)(249.0m)(110.0m)
show all
USDY, 2020

EV/EBIT

100.6 x

EV/CFO

151.3 x

Financial Leverage

2.5 x
Show all financial metrics

Baxter International Acquisitions / Subsidiaries

Company NameDateDeal Size
Cheetah MedicalSeptember 10, 2019$230 m

Baxter International Online and Social Media Presence

Baxter International's Trends

Embed Graph

Baxter International Company Culture

  • Overall Culture

    D

    61/100

  • CEO Rating

    D

    61/100

  • Compensation

    C-

    63/100

  • Diversity

    D

    62/100

Learn more on Comparably

Baxter International News and Updates

December 07, 2019

BAXTER LOSS ALERT: ROSEN LAW FIRM Reminds Baxter International Inc. Investors of Important January 24th Deadline in Securities Class Action

NEW YORK, Dec. 7, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Baxter International Inc. between February 21, 2019 and October 23, 2019, inclusive (the "Class Period") of the important January 24, 2020 lead plaintiff...
December 03, 2019

ROSEN, A HIGHLY RANKED FIRM, Announces Filing of Securities Class Action Lawsuit Against Baxter International Inc. - BAX

NEW YORK, Dec. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Baxter International Inc. (NYSE: BAX) between February 21, 2019 and October 23, 2019, inclusive (the "Class...
November 27, 2019

Hagens Berman, NATIONAL TRIAL ATTORNEYS, Encourages Baxter International (BAX) Investors with $100k+ Losses to Contact its Attorneys, Securities Fraud Lawsuit Filed Concerning Admitted Improper Accounting

SAN FRANCISCO, Nov. 26, 2019 /PRNewswire/ -- Hagens Berman urges Baxter International (NYSE: BAX) investors who have suffered losses in excess of $100,000 to submit their losses now to learn if they qualify to recover compensable damages. A securities fraud class action has been filed...
November 26, 2019

Kessler Topaz Meltzer & Check, LLP Files A Shareholder Class Action Lawsuit Against Baxter International Inc. For Violations Of Federal Securities Laws

RADNOR, Pa., Nov. 25, 2019 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that the firm has filed a securities fraud class action lawsuit against Baxter International Inc. (NYSE: BAX) ("Baxter") on behalf investors who purchased or otherwise acquired Baxter...
November 02, 2019

BAXTER INTERNATIONAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Baxter International Inc. for Possible Securities Fraud - BAX

NEW ORLEANS, Nov. 1, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Baxter International Inc. (NYSE: BAX). KSF's investigation is...
October 25, 2019

Hagens Berman, NATIONAL TRIAL ATTORNEYS, Notifies Baxter International (BAX) Investors of Investigation of Possible Securities Fraud: Encourages Investors with Significant Losses to Contact Firm

SAN FRANCISCO, Oct. 24, 2019 /PRNewswire/ -- Hagens Berman notifies Baxter International (NYSE: BAX) investors of the firm's investigation of possible violations of federal securities laws. The firm urges Baxter International investors who have suffered losses in excess of $50,000 to...
Show more

 Baxter International Frequently Asked Questions

  • When was Baxter International founded?

    Baxter International was founded in 1931.

  • Who are Baxter International key executives?

    Baxter International's key executives are Jose Almeida, E. Almeida and Amy A. Wendell.

  • How many employees does Baxter International have?

    Baxter International has 50,000 employees.

  • What is Baxter International revenue?

    Latest Baxter International annual revenue is $11.4 b.

  • What is Baxter International revenue per employee?

    Latest Baxter International revenue per employee is $227.2 k.

  • Who are Baxter International competitors?

    Competitors of Baxter International include Medtronic, Fresenius and Becton Dickinson.

  • Where is Baxter International headquarters?

    Baxter International headquarters is located at 1 Baxter Pkwy, Deerfield.

  • Where are Baxter International offices?

    Baxter International has offices in Deerfield, Baltimore, Bedford, Bloomington and in 34 other locations.

  • How many offices does Baxter International have?

    Baxter International has 38 offices.